Skip to main content
SpringerLink
Log in

Unresectable, Locoregionally Advanced Head and Neck Cancer

  • Chapter
Book cover Head and Neck Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 114))

  • 290 Accesses

Conclusion

There has been considerable progress in the treatment of locally advanced, unresectable head and neck cancer in the last 2 decades. Concurrent chemoradiotherapy has been proven superior to radiotherapy alone with 5 year survival rates of greater than 50% in some of the investigational intensified chemoradiotherapy programs. At this time the combination of high dose cisplatin and standard fractionated radiotherapy should be considered the community standard based on the results of the Head and Neck Intergroup Study which proved superior survival when compared to radiation therapy alone or split course multi agent chemoradiotherapy and proved the feasibility of safely administering the regimen in the community setting. However, whenever possible, referral to institutions experienced in the treatment and care of patients receiving intensified chemoradiotherapy and enrollment in appropriate clinical trials should be encouraged.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Vokes E.E., Werchselbaum R.R., Lippman S.M., Hong W.K. Head and neck cancer. NEngl JMed 1993; 328:184–194

    CAS  Google Scholar 

  2. Al-Sarraf M, Le Blanc M., Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1320–1317

    Google Scholar 

  3. Department of Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685–1690

    Google Scholar 

  4. Lefevre J.L., Chevalier D., Luboinski B., et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European organization research and treatment of cancer phase III trial. J Natl Cancer Inst 1996; 88: 890–899

    Google Scholar 

  5. Forastiere A., Goepfert H., Goffinet D., et al. NCCN practice guidelines for head and neck cancer. National Comprehensive Cancer Network. Oncology 1998; 12: 39–147

    CAS  Google Scholar 

  6. Fu K.K., Phillips T.L., Silverberg I.J., et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a northern California oncology group randomized trial. J Clin Oncol 1987; 5(9): 1410–1414

    PubMed  CAS  Google Scholar 

  7. Aisner J., Jacobs M., Sinabladi V., et al. Chemoradiotherapy for the treatment of regionally advanced head and neck cancers. Seminars in Oncology 1994; 21(5) Suppl 12:35–44

    PubMed  CAS  Google Scholar 

  8. List M.A., Siston A., Haraf D., et al. Quality of life and performance in advanced head and neck cancer patients on concomtant chemoradiotherapy: a prospective examination. J Clin Oncol 1999; 17:1020–1028

    PubMed  CAS  Google Scholar 

  9. Browman G.P., Hodson D.I., Mackenzie, R.G., et al. Concomitant chemotherapy and radiotherapy in squamous cell head and neck cancer (excluding nasopharynx). Head Neck 2001 (in press)

    Google Scholar 

  10. Lo T.C., Wiley A.L. Jr., Ansfield F.J., et al. Combined radiation therapy and 5-flourouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. Am J Roentgenol 1976; 126: 229–235

    CAS  Google Scholar 

  11. Shanta V., Krishnamurthi S. Combined bleomycin and radiotherapy in oral cancer. Clin Radio 1980; 31: 617–620

    CAS  Google Scholar 

  12. Forastiere A.A. Overview of platinum chemotherapy in head and neck cancer. Seminars in Oncology 1994; 21(5) Supp 12:20–27

    PubMed  CAS  Google Scholar 

  13. Al-Sarraf M. Cisplatin combinations in the treatment of head and neck cancer. Seminars in Oncology 1994; 21(5) Suppl 12:28–34

    PubMed  CAS  Google Scholar 

  14. Adelstein D.J. Induction chemotherapy in head and neck cancer. Hematology/Oncology Clinics North America 1999; (13)4: 689–698

    Google Scholar 

  15. Fu K.K. Combined-modality therapy for head and neck cancer. Oncology 1997; 11(12): 1781–1800

    PubMed  CAS  Google Scholar 

  16. Brockstein B.E., Vokes, E. E. Chemoradiotherapy for head and neck cancer. PPO Updates/Principles and Practice of Oncology. 1996; 10(9): 1–19

    Google Scholar 

  17. Forastiere A. A., Trotti A. Radiotherapy and concurrent chemotherapy: a strategy that improves locoregional control and survival in oropharyngeal cancer. J Natl Cancer Inst 1999; 91(24): 2065–2066

    Article  PubMed  CAS  Google Scholar 

  18. Munro A.J. An overview of randomized trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995; 71: 83–91

    PubMed  CAS  Google Scholar 

  19. El-Sayed S., Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective and randomized trials. J Clin Oncol 1996; 14(3): 838–847

    PubMed  CAS  Google Scholar 

  20. Pignon J.P., Bourhis J., Domenge C., Designé L. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet 2000; 355:949–955

    PubMed  CAS  Google Scholar 

  21. Bourhis J., Pignon J.P. Meta-analyses in head and neck squamous cell carcinoma: what is the role of chemotherapy? Hematology/Oncology Clinics of North America 1999; 13(41): 769–775

    PubMed  CAS  Google Scholar 

  22. Head and Neck Contracts Program. Adjuvant chemotherapy for advanced head and neck squamous carcinoma: final report of the head and neck contracts program. Cancer 1987; 60(3): 301–311

    Google Scholar 

  23. Laramore G.E., Scott C.B., Al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup study 0034. Int Radiat Oncol Biol Phys 1992; 23: 705–713

    CAS  Google Scholar 

  24. AI-Sarraf M., Pajak T., Laramure G., et al. Radiotherapy versus chemotherapy followed by RT in resected and negative margins head and neck cancers. Intergroup study 0034: final analysis. Pro Am Soc Clin Oncol 1997; 16: 392a (abstr 1399)

    Google Scholar 

  25. Bachaud J.M., Cohen-Jonathan E., Alzieu C., et al. Combined post-operative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996; 36: 999–1004

    Article  PubMed  CAS  Google Scholar 

  26. AI-Sarraf M., Pajak T.F., Byhardt R.W., et al. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, respectable head and neck cancers: TROG 88–24. Int J Radiat Oncol Biol Phys 1997; 37(4): 777–782

    Google Scholar 

  27. Posner M.R., Colevas A.D., Tishler R.B. The role of induction chemotherapy in the curative treament of squamous cell caner of the head and neck. Seminars in Oncology 2000; 27(4) Suppl 8: 13–24

    PubMed  CAS  Google Scholar 

  28. Forastiere A.A., Berlsey B., Maor M., et al. Phase III trial to preserve larynx: induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, intergroup trial R91-11. Proc Am Soc Clin Oncol 2001; 20: 2a (abstr 4)

    Google Scholar 

  29. Paccagnella A., Orlando A., Marchiori C., et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994; 86(4): 265–272

    PubMed  CAS  Google Scholar 

  30. Kies M.S., Haraf D.J., Athanasiadis I., et al. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol 1998; 16:2715–2721

    PubMed  CAS  Google Scholar 

  31. Browman G.P. Evidence-based recommendation against neoadjuvant chemotherapy for routine management of patients with squamous cell head and neck cancer. Cancer Invest 1994; 12(6): 662–670

    PubMed  CAS  Google Scholar 

  32. Harari P.M. Why had induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? J Clin Oncol 1997; 15(5): 2050–2055

    PubMed  CAS  Google Scholar 

  33. Harari P.M., Cleary J.F., Hartig G.K. Evolving patterns of practice regarding the use of chemoradiation for advanced head and neck cancer patients. Proc Am Soc Clin Oncol 2001; 20: 226a (abstr 903)

    Google Scholar 

  34. Fu K.K., Pajak T.F., Trotti A., et al. A radiation therapy oncology group phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation radiotherapy for head and neck squamous cell carcinomas: preliminary results ofRTOG 9003. Int J Radiat Oncol Biol Phys 1999; 45(Suppl): 145 (abstr 1)

    Google Scholar 

  35. Vokes E.E., Haraf D.J., Kies M.S. The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer. Seminars in Oncology 2000; 27(4) Suppl 8: 34–38

    PubMed  CAS  Google Scholar 

  36. Vokes E.E. Interactions of chemotherapy and radiation. Seminars in Oncology 1993; 20(1): 70–79

    PubMed  CAS  Google Scholar 

  37. Haffty B.G. Concurrent chemoradiation in the treatment of head and neck cancer. Hematology/Oncology Clinics of North America 1999; 13(4): 719–742

    Article  PubMed  CAS  Google Scholar 

  38. Haffty B.G., Son Y.H., Rose P., et al. Chemotherapy as and adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale mitimycin randomized trials. JClin Oncol 1997; 15(1): 268–276

    CAS  Google Scholar 

  39. Browman G.P., Cripps C., Hodson D.J., et al. Placebo-controlled randomized trial of infusional flourouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 1994; 12(12): 2648–2653

    PubMed  CAS  Google Scholar 

  40. Gupta N.K., Pointon R.C.S., Wilkinson P.M. A randomized clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Clin Radiol 1987; 38: 575–581

    PubMed  CAS  Google Scholar 

  41. Taylor S.G., Murthy A.K., Vannetzel J.M., et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 1994: 12(2):385–395

    PubMed  Google Scholar 

  42. Merlano M., Benasso M., Corvó R., et al. Five year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996; 88(19): 583–589

    PubMed  CAS  Google Scholar 

  43. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91(24): 2081–2086

    Article  PubMed  CAS  Google Scholar 

  44. Adelstein D.J., Adams G.L., Ly Y., et al. A phase III comparison of standard radiation therapy (RT) versus RT plus concurrent cisplatin (Ddp) versus split-course RT plus concurrent Ddp and 5-Flourouracil in patients with unresectable squamous cell head and neck cancer: an intergroup study. Proc Am Clin Oncol 2000; 19: (abstr 1624)

    Google Scholar 

  45. Weissler M.L., Melin S., Sailer S.L., et al. Simultaneous chemoradiation in the treatment of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 1992; 118: 806–810

    PubMed  CAS  Google Scholar 

  46. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338(25): 1798–1804

    Article  PubMed  CAS  Google Scholar 

  47. Wendt T. G., Grabenbauer G.G., Rödel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998; 16(4): 1318–1324

    PubMed  CAS  Google Scholar 

  48. Jeremic B., Shibamoto Y., Milici B., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000; 18(7): 1458–1464

    PubMed  CAS  Google Scholar 

  49. Vokes E.E., Haraf D.J., Stenson K., et al. The role of paclitaxel in the treatment of head and neck cancer. Seminars in Oncology 1995; 22(5) Suppl 12: 8–12

    PubMed  CAS  Google Scholar 

  50. Chougule P., Wanebo M., Akerley W., et al. Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study — preliminary results. Seminars Oncol 1997; 24(6) Suppl 19: 57–61

    CAS  Google Scholar 

  51. Conley B., Jacobs M., Suntharalingam M., et al. A pilot trial of paclitaxel, carboplatin, and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck. Seminars Oncol 1997; 24(11) Suppl 2: 78–80

    Google Scholar 

  52. Kies M., Haraf D.J., Rosen F., et al. Concomitant infusional paclitaxel and flourouracil, oral hydroxyurea, and Hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 2001; 19(7): 1961–1969

    PubMed  CAS  Google Scholar 

  53. Wanebo H.J., Chougule P., Ready N., et al. Pre-operative therapy with reduced dose paclitaxel, and carboplatin and radiation achieves a similar complete response rate to a high dose regimen, but with reduced toxicity. Proc Am Soc Clin Oncol 2000; 19: (Abstr 1655)

    Google Scholar 

  54. Grem J.L. “Flourinated Pyrimidines.” In Cancer Chemotherapy Principles and Practice, B.A. Chabner and J.M. Collins, eds. Philadelphia, PA: JB Lippincott, 1990

    Google Scholar 

  55. Haraf D.J., Vokes E.E., Panje W.R., Weichselbaum R.R. Survival and analysis of failure following hydroxyurea, 5-Flourouracil and concomitant radiation therapy in poor prognosis head and neck cancer. Am J Clin Oncol 1991; 14: 419–422

    PubMed  CAS  Google Scholar 

  56. Vokes E.E., Panje W.R., Schilsky R.L., et al. Hydoxyurea, flourouracil, and concomitant radiotherapy in poor prognosis head and neck cancer: a phase I-II study. J Clin Oncol 1989; 7: 761–768

    PubMed  CAS  Google Scholar 

  57. Vokes E.E., Kies M.S., Haraf D.J., et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000; 18(8): 1652–1661

    PubMed  CAS  Google Scholar 

  58. Rosen F.R., Haraf D., Brackstein B., et al. Multicenter randomized phase III study of 1 hour infusion paclixel, flourouracil and hydroxyurea with concomitant Hyperfractionated radiotherapy with or without erythropoietin for advanced head and neck cancer. Proc Am Soc Clin Oncol 2001; 20: 226a (abstr 902)

    Google Scholar 

  59. Adelstein D.J., Saxton J.P., Lavertu P., et al. Maximizing local control and organ preservation in advanced squamous head and neck cancer with Hyperfractionated radiation and concurrent chemotherapy. Proc Am Soc Clin Oncol 2001; 20:224a (abstr 893)

    Google Scholar 

  60. Garden A.S., Pajak T.F., Vokes E., et al. Preliminary results of TROG 9703 — a phase II randomized trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. Proc Am Soc Clin Oncol 2001; 20: 223a (abstr 891)

    Google Scholar 

  61. Garden A.S., Glisson B.S., Ang K.K., et al. Phase I/II trial of radiation with chemotherapy “boost” for advanced squamous cell carcinomas of the head and neck: toxicities and responses. J Clin Oncol 1999; 17(8): 2390–2395

    PubMed  CAS  Google Scholar 

  62. Boyd T.S., Jarari P.M., Tannehill S.P., et al. Planned post radiotherapy neck dissection in patients with advanced head and neck cancer. Head Neck 1998; 20(2): 132–137

    Article  PubMed  CAS  Google Scholar 

  63. Sanguineti G., Corvo R., Benasso M., et al. Management of the neck after alternating chemoradiotherapy for advanced head and neck. Head Neck 1999; 21(3): 223–228

    Article  PubMed  CAS  Google Scholar 

  64. Naravan K., Crane C.H., Kleid S., Hughes P.G., Peters L.J. Planned neck dissection as an adjunct to the management of patients with advanced neck disease treated with definitive radiotherapy: for some or for all? Head Neck 1999; 21(7): 606–613

    Google Scholar 

  65. Yuhas J.M., Spellman J.M., Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 1980; 3: 211–216

    PubMed  CAS  Google Scholar 

  66. Utley J.F., Marlowe C., Waddell W.J. Distribution of 355 — labeled WR-2721 in normal and malignant tissues of the mouse. Radiat Res 1976; 68:284–291

    PubMed  CAS  Google Scholar 

  67. Buntzel J., Kuttner K., Frohlich D., et al. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 1998; 9: 505–509

    PubMed  CAS  Google Scholar 

  68. Rosen F.R., Chung T.D., Portugal L., et al. Amifostine, concomitant cisplatin, paclitaxel and re-irradiation in recurrent head and neck cancer. Proc Am Soc Clin Oncol 2000; 19: 427a (abstr 1686)

    Google Scholar 

  69. Brizel D. M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18(19): 3339–3345

    PubMed  CAS  Google Scholar 

  70. Johnson J.T., Ferretti G.A., Nethery W.J., et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993; 329(6): 390–395

    Article  PubMed  CAS  Google Scholar 

  71. LeVeque F.G., Montgomery M., Potton D., et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 1993; 11(6): 1124–1131

    PubMed  CAS  Google Scholar 

  72. Scarantino C.W., Le Vegue F.G., Scott C.B., et al. A phase III study of concomitant oral pilocarpine to reduce hypo-salivation and mucositis associated with curative radiation therapy in head and neck cancer patients. RTOG 9709. Am Soc Clin Oncol 2001; 20:225a (abstr 897)

    Google Scholar 

  73. Eisbruch A., Shewach D., Urba S., et al. Phase I trial of radiation concurrent with low dose gemcitabine for head and neck cancer: high mucosal and pharyngeal toxicity. Pro Am Soc Clin Oncol 1997; 16: 386a (abstr 1377)

    Google Scholar 

  74. Regine W.F., Valentino J., Arnold S.M., et al. High-dose intra-arterial cisplatin boost with Hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2001; 19(14): 3333–3339

    PubMed  CAS  Google Scholar 

  75. Bradford C. Predictive factors in head and neck cancer. Hematology Oncology Clinics of North America 1999; 13(4): 777–785

    Article  CAS  Google Scholar 

  76. ._Brennan J. A., Mao L., Hruban R.H., et al. Molecular assessment ofhistopathologic staging. N Engl J Med 1995

    Google Scholar 

  77. Koch W. Biomarker predictors of response to chemoradiation therapy for head and neck squamous cell carcinoma. American Society of Clinical Oncology Educational Book: 36th Annual Meeting, Spring 2000, Michael C. Perry, ed.

    Google Scholar 

  78. Teman S., Flahault A., Périé S., et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2000; 18(27): 385–399

    Google Scholar 

  79. Clayman G.L., el-Naggar A.K., Lippman S.M., et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 2221–2232

    PubMed  CAS  Google Scholar 

  80. Goodwin W.J., Esser D., Clayman G., et al. Randomized phase II study of intratumoral injection of two dosing schedules using a replication-deficient adenovirus carrying the p53 gene (ADSCMV-p53) in patients with recurrent/refractory head and neck cancer. Proc Am Soc Clin Oncol 1999; 18: 445a (abstr 1717)

    Google Scholar 

  81. Kirn D.H., Khuri F., Ganly I., et al. A phase II trial of ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-flourouracil in patients with recurrent head and neck cancer. Proc Am Soc Clin Oncol 1999; 18: 389a (abstr 1505)

    Google Scholar 

  82. Khuri F.R., Nemunatis J., Ganly I., et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Medicine 2000; 6(8): 879–885

    Article  PubMed  CAS  Google Scholar 

  83. Clayman G.L. The current status of gene therapy. Seminars in Oncology 2000; 27(4) Suppl 8: 39–43

    PubMed  CAS  Google Scholar 

  84. Grandis J.R., Melhern M.F., Gooding W.E., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824–832

    Article  Google Scholar 

  85. Mendelsohn J. Epidermal growth factor receptor inhibition by monoclonal antibody as anticancer therapy. Clin Cancer Res 1997; 3: 2703–2707

    PubMed  CAS  Google Scholar 

  86. Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol 2000; 18(21s): 54s–59s

    PubMed  CAS  Google Scholar 

  87. Baselga J., Herbst R., La Russo P., et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor in patients with five selected tumor types: evidence of activity and good tolerability. Pro Am Soc Clin Oncol 2000; 19: 177a (abstr 686)

    Google Scholar 

  88. Baselga J., Pfister D., Cooper M.R., et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904–914

    PubMed  CAS  Google Scholar 

  89. Robert F., Ezekiel M., Spencer S., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck caner. J Clin Oncol 2001; 19(13): 3234–3243

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, 60612

    Fred Rosen M.D.

Authors
  1. Fred Rosen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Evanston Northwestern Healthcare, Evanston, IL

    Brockstein Bruce M.D.  & Masters Gregory M.D.  & 

  2. Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, IL

    Brockstein Bruce M.D.  & Masters Gregory M.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Kluwer Academic Publishers

About this chapter

Cite this chapter

Rosen, F. (2004). Unresectable, Locoregionally Advanced Head and Neck Cancer. In: Bruce, B., Gregory, M. (eds) Head and Neck Cancer. Cancer Treatment and Research, vol 114. Springer, Boston, MA. https://doi.org/10.1007/0-306-48060-3_10

Download citation

  • DOI: https://doi.org/10.1007/0-306-48060-3_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-7336-6

  • Online ISBN: 978-0-306-48060-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation